01.10.2014 • NewsJames GalloglyLyondellBasell

LyondellBasell CEO Gallogly to Retire in 2015

James Gallogly, CEO of LyondellBasell since May 2009, will retire in early 2015, the company has announced.

A committee of the supervisory board has been appointed to find a successor.

The contract of the 61-year-old executive, who steered LyondellBasell through its post-bankruptcy reorganization, was last renewed for four years in May of this year. However, "having achieved the goals that I set for myself professionally and for the company," Gallogly said, "I feel it is time to move on to the next chapter.

Collectively appointed to four-year terms in May, "the entire management board has demonstrated exceptional business leadership and I am confident the transition will be seamless," the retiring CEO added.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.